SAN FRANCISCO , May 5, 2022 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022.     Cash and investments in marketable securities at March 31, 2022 were approximately $704.4 million as compared to $798.8 million at December

Original Source


Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219